Abstract. 4-Hydroxy-2-nonenal (HNE), a potent toxin formed in the brain from oxidation of polyunsaturated fatty acids, is increased in Alzheimer disease (AD), where it is a proposed effector of amyloid ␤ peptide-mediated neurotoxicity. Detoxification of HNE via the mercapturic acid pathway (MAP) is the primary means by which other organs, such as liver, limit its toxic effects. Here we examined the distribution and activity of MAP detoxification for HNE in cerebrum. Our results showed that rat cerebral cortex and especially synaptosomes were less well equipped to detoxify HNE via the MAP than liver. Glutathione transferases (GSTs) catalyze the committed step in the MAP; GST-mu and GST-pi, but not GST-alpha, were detected in neurons and astrocytes in cerebrum from AD patients and controls. MAP activity in frontal cortex of AD patients was modestly but significantly increased compared to controls. These data suggest that lipid peroxidation may present a greater toxic burden to cerebrum than to other organs, and that a component of response to injury in late stage AD is a slight increase in MAP activity.
INTRODUCTION
Increased oxidative damage is an important component in the pathogenesis of several age-related neurodegenerative diseases, including Alzheimer disease (AD). A major consequence of oxidative damage to brain is lipid peroxidation, and one of the most biologically potent products of lipid peroxidation is 4-hydroxy-2-nonenal (HNE). HNE's neurotoxicity results from its covalent modification of cellular nucleophiles. Indeed, HNE-protein adduction is an effector of amyloid beta (A␤) peptide-mediated neurotoxicity in vitro (1) (2) (3) . Immunohistochemical analysis has shown increased HNE-protein adduct accumulation in diseased regions of brain from patients with AD (4-6), and cerebrospinal fluid concentrations of HNE are elevated in patients with AD compared to age-matched controls (7) .
The balance between normal and deleterious concentrations of HNE is governed not only by the rates of production but also metabolic detoxification. Numerous enzymes have evolved that detoxify HNE and related aldehydes. The major route of HNE metabolism in heart, kidney, and liver is the mercapturic acid pathway (MAP) with glutathione (GSH) conjugation to HNE catalyzed by glutathione transferases (GSTs) as the first step (Fig. 1 ). In addition, the aldehyde dehydrogenases (ALDH), of which only mitochondrial ALDH2 is detectable in brain, detoxify HNE by catalyzing its oxidation to the corresponding organic acid, 4-hydroxynonenoic acid (HNA) (8, 9) , and several enzymes catalyze reduction of HNE to its corresponding diol, 1,4-dihydroxynonene (DHN); of these only aldose reductase was detected in human cerebrum (10) .
Given that MAP metabolism is the major detoxification route for HNE in other organs, several studies have examined GST-mediated metabolism of HNE in neuronal systems. In vitro data indicate that GST activity may be neuroprotective since transfection of rat primary neuronal cultures with GST cDNA protects them from HNE exposure (11) . However, tissue from diseased regions of brain and ventricular fluid from AD patients have normal or decreased GST activity compared to controls, and there is no difference between AD patients and controls in expression of a specific GST, hGSTA4-4, that is particularly efficient at catalyzing HNE conjugation with GSH. Thus, it remains unclear to what extent the MAP detoxifies HNE in brain and whether or not activity in this pathway is increased in response to injury that occurs in patients with AD.
MATERIALS AND METHODS Materials
Rabbit anti-human alpha, mu and pi classes of GST were obtained from Novocastra Laboratories (Newcastle upon Tyne, UK). Chemicals required for the synthesis of HNE were obtained from Aldrich (Milwaukee, WI). All chemicals not otherwise specified were obtained from Sigma Chemicals (St. Louis, MO). Protein concentration was determined using the Bio-Rad DC Protein assay (Hercules, CA). . Adduction of glutathione (GSH) to HNE is the committed step in MAP metabolism and is catalyzed by glutathione-S-transferases (GST). The glutathionyl-HNE thioether adduct is further metabolized by ␥-glutamyltranspeptidase (␥-GT) and dipeptidases (DP) to the cysteinyl (CYS)-HNE thioether adduct. The cysteinyl thioether adduct is a substrate for acetyltransferases (AT) that catalyze the acetylation of the cysteinyl adduct to generate the acetylcysteinyl (AcCYS), or mercapturic acid, adduct. This last step can be reversed by one of several acylases.
2 H-HNE was synthesized according to published protocol (13), using bromopentane-d 11 (Isotec, Miamisburg, OH). Glutathionyl-, cysteinyl-, and mercapturyl-HNE (GSH-HNE, Cys-HNE, and Mer-HNE, respectively) were synthesized by incubating a 2-fold excess of HNE with GSH, cysteine, or N-acetylcysteine in potassium phosphate buffer, pH 7.4, and stirring for 2 hours. Adducts were purified on an HPLC-UV system monitored at 223 nm using a 10-mM acetic acid /acetonitrile gradient with an Inertsil ODS-2 5 m semi-prep column (AnSys Technologies, Inc., Lake Forest, CA). Tritiated and deuterated adducts were made as above using 3 H-HNE or 2 H-HNE, respectively. HNA and DHN were synthesized according to established methods (14, 15) .
Human Tissue
All tissue was from individuals who volunteered to participate in IRB-approved rapid autopsy protocols at Vanderbilt University. Postmortem interval (PMI) was less than 4 hours in all cases. At autopsy, tissue was dissected, frozen in liquid nitrogen, and then stored at Ϫ80ЊC until analyzed, or fixed in formalin, embedded in paraffin, and used for immunohistochemistry. All patients with AD were diagnosed as probable AD during life and had pathological diagnoses made according to established criteria (16) . Control individuals showed age-related changes only on neuropathologic examination.
Tissue Homogenates and Synaptosomes
Adult male Sprague-Dawley rats (300-350 g, Harlan, Indianapolis, IN) were maintained in a vivarium with a 12-12 hour light-dark cycle and food and water provided ad libitum. For tissue homogenate experiments, whole rat cerebral cortex including hippocampus or rat liver was removed immediately after death into ice-cold Krebs-Henseleit (KH) buffer (in mM: NaCl 118, KCl 4.7, MgCl 2 1.25, CaCl 2 3, KH 2 PO 4 1.25, EDTA 0.5, HEPES 25, and glucose 10). Tissue was homogenized on ice for 1 min at 60% power in a VirTis Cyclone Virtishear (Gardiner, NY) and used in experiments at a protein concentration of 1 mg/ml. Rat cerebral cortical synaptosomes were prepared according to standard protocol (17) and ultimately diluted to 1 mg/ml protein in KH buffer. One rat yielded approximately 10 homogenate or synaptosome preparations. Human cerebral cortical tissue homogenates were prepared from frozen middle frontal gyrus, a region extensively involved by AD, as described for rat cerebral cortex.
Quantification of HNE, HNA, and DHN
To measure HNE, HNA, and DHN, synaptosomes or tissue were incubated in a shaking 37ЊC water bath with 100 M HNE. Reaction was stopped by removing 100 l from incubation and adding it to 100 l of 100 mM acetic acid, placing it on ice, and centrifuging at 14,000 ϫ g for 30 min. Supernatant was removed and stored at Ϫ80ЊC until analysis. The reaction at time zero was performed by adding tissue or synaptosomes to HNE already in acetic acid. At all time points, parallel samples of tissue preparations that had been boiled at 100ЊC for 15 min were used to assess nonenzymatic conversion of HNE.
HNE and HNA were quantitated by HPLC-UV at 223 nm using a Waters Spherisorb ODS-2 column (4.6 ϫ 250 mm, 5 m, Waters Corp., Milford, MA) and an isocratic 10 mM acetic acid/40% acetonitrile mobile phase. A standard curve of authentic standards was run each day. DHN was measured using a negative ion chemical ionization gas chromatography/mass spectrometry (NICI-GC/MS) system. Experimental aliquots were incubated with hydroxylamine reagent (including decane diol as an internal standard) for 1 to 5 min at 65ЊC and then extracted though a Waters C18 column into methanol. The eluant was dried thoroughly and then derivatized in equal volumes of anhydrous acetonitrile: N-Methyl-N-(tert-butyldimethylsilyl) trifluoroacetamide (MTBSTFA) plus 1% tert-butyldimethylchlorosilane (TBDMCS) (Regis Technologies, Morton Grove, IL) for 60 min at 100ЊC. One microliter was injected into a GC-MS and monitored for appropriate ions.
Quantification of Hydrophilic Metabolites and Protein Bound 3 H-HNE
Tritiated standards of HNE, GSH-, Cys-, and Mer-HNE were followed through an extraction method of equal volumes of 100 mM acetic acid and chloroform. Samples were vortexed for 1 min and then centrifuged at 3,000 ϫ g for 5 min and organic and aqueous phases removed into separate scintillation vials. After drying, 5 ml Econo-Safe scintillation cocktail (Research Products International Corp (RPI), Mount Prospect, IL) was added to each vial and radioactivity measured in a Packard 1900CA Liquid Scintillation Analyzer (Meriden, CT).
To follow conversion of 3 H-HNE to its hydrophilic metabolites, synaptosomes or tissue were incubated in a shaking 37ЊC water bath with 100 M 3 H-HNE. The reaction was stopped by removing 100 l from incubation and adding it to 1 ml of equal volumes of 100 mM acetic acid and chloroform. As described for HNE, HNA and DHN measurements, time zero was determined by adding 3 H-HNE to tissue or synaptosomes already in acetic acid/chloroform while parallel boiled samples were used to assess nonenzymatic conversion. , and synaptosomes (C) for the percentage of total HNE consumed or converted to hydrophilic metabolites via the MAP. Tissue preparations were incubated at 37ЊC with 100 M HNE for 1 to 5 min, HNE remaining was measured by HPLC-UV monitored at 223 nm. Two-way ANOVA (F 2,5,113 ) for the percent of HNE consumed at the different time points vs tissue source was highly significant for both tissue (p Ͻ 0.0001) and time (p Ͻ 0.0001). Alternatively, tissue preparations were incubated with 100 M 3 H-HNE for 1 to 5 min and the percentage of total radioactivity added that was enzymatically converted into hydrophilic products determined. Two-way ANOVA (F 2,5,86 ) for the percent of 3 H-HNE converted into hydrophilic metabolites at the different time points vs tissue source was highly significant for both tissue (p Ͻ 0.0001) and time (p Ͻ 0.0001).
Protein bound HNE was determined by incubating tissue preparations in a shaking 37ЊC water bath with 100 M 3 H-HNE for 5 min. Protein was precipitated with ice-cold 50% perchloric acid, sedimented at 10,000 ϫ g, and the precipitated protein washed twice with ice-cold perchloric acid. Radioactivity retained in the protein pellet was quantified using a liquid scintillation counter as described above.
Immunohistochemistry
Immunohistochemistry was performed as previously described (18) on formalin-fixed, paraffin-embedded sections with the following dilutions: GST-alpha 1:50, GST-mu 1:50, and GST-pi 1:100. According to manufacturer's suggestions, positive control tissue was human testis for GST-mu; human small intestinal epithelium for GST-alpha; and human liver for GST-pi. All positive control tissue were formalin-fixed and paraffin-embedded exactly the same as brain and liver tissue.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism version 3.0 for Windows, GraphPad Software, www.graphpad.com (San Diego, CA). Two-way analysis of variance (ANOVA) was performed on data sets followed by Bonferroni's corrected multiple comparison post tests when appropriate.
RESULTS

Metabolism of HNE by Rat Liver, Cerebral Cortex, and Synaptosomes
Free HNE may be lost via metabolism or covalent binding to macromolecules. We determined the sum of these processes by assaying free HNE following incubation with rat tissue (Fig. 2A) . We selected 100 M HNE in these incubations to insure conditions of substrate excess, so that any differences in the amount of HNE metabolized quantitatively reflect the capacity of the tissue to metabolize HNE. HNE metabolism in rat liver has been studied extensively, therefore, we included rat liver as a positive control. Following 1-minute incubation of HNE with rat liver, 67% of the added HNE was no longer detectable as free HNE. After this initial reduction in HNE, no significant further loss was noted for up to 5 min. In rat cerebral cortical homogenate (Fig.  2B) , approximately half of the added HNE was consumed in the first minute without subsequent significant loss. Rat cerebral synaptosomes metabolized HNE the slowest with only 36% of added HNE consumed after 1 min (Fig.  2C) . The percent of HNE consumed at the different time points vs rat tissue source (liver, cerebral cortex, or synaptosomes) was highly significant for both tissue source (p Ͻ 0.0001) and time (p Ͻ 0.0001). The percent of HNE consumed by liver homogenates was significantly different from cerebral cortex and synaptosomes at all times Ն1 min (p Ͻ 0.05), while cerebral cortex and synaptosomes were not significantly different at any time point. No further consumption of HNE was observed out to 60 min incubation in any of the 3 tissue preparations (not shown).
MAP metabolism converts lipophilic HNE into one of at least a dozen different hydrophilic metabolites. Using synthetic standards, we determined that during acetic acid/chloroform extraction 93% Ϯ 4% of 3 H-HNE partitioned into the organic layer. In contrast, 97% Ϯ 3%, 95% Ϯ 3%, and 98% Ϯ 2% of GSH-, Cys-, and Mer-3 H-HNE, respectively, partitioned into the aqueous phase. To determine the contribution of MAP activity to the observed loss of HNE in different rat tissue, we assayed the metabolic conversion of lipophilic 3 H-HNE into hydrophilic metabolites (Fig. 2) . Data are expressed as total activity minus activity present in paired boiled tissue preparations to reflect only enzyme-catalyzed reactions. As expected, rat liver homogenates metabolized HNE to hydrophilic metabolites at a rate that was very similar to the total consumption of HNE by rat liver homogenates (Fig. 2A) . Rat cerebral cortex homogenates metabolized 3 H-HNE much less extensively with only 13% of added radioactivity enzymatically converted to hydrophilic metabolites after 5 min (Fig. 2B) . Rat cerebral synaptosomes metabolized the least amount of HNE to hydrophilic metabolites with only approximately 5% of HNE metabolized during the 5-minute incubation (Fig. 2C) . The percent of HNE converted into hydrophilic metabolites at the different time points vs rat tissue source (liver, cerebral cortex, or synaptosomes) was highly significant for both tissue source (p Ͻ 0.0001) and time (p Ͻ 0.0001). The percent of HNE consumed by liver homogenates was significantly different from cerebral cortex and synaptosomes at all times Ն1 min (p Ͻ 0.01). Similar to total HNE consumed, the amount of HNE converted to hydrophilic metabolites was not significantly different between cerebral cortex and synaptosomes at all time points. As with total HNE consumed, no further increase in hydrophilic metabolites of HNE beyond what was observed at 5 min was observed when the reactions were incubated for 60 min (not shown).
We next analyzed the data presented in Figure 2 to compare the percentage of HNE consumed vs percentage of HNE metabolized to hydrophilic metabolites for rat liver, cerebral cortex, and synaptosomes. All showed highly significant variance with respect to time (p Ͻ 0.0001). In contrast, only cerebral cortex (p Ͻ 0.001) and synaptosomes (p Ͻ 0.0001) showed a significant difference between total HNE consumption and MAP metabolism; there was no significant difference in these to measures from liver. This indicates that in liver, MAP metabolism accounted for virtually all of the HNE consumed, while in cerebrum, MAP metabolism was responsible for only a small fraction of the HNE lost. Therefore, we next pursued other possible pathways by determining both the oxidation of HNE to its corresponding organic acid, HNA, and reduction to its alcohol, DHN. Under the same reaction conditions as those described above, enzyme-derived HNA levels were 2.2%, 1.6%, and 2.5% of total HNE added in liver, cerebral cortex, and synaptosomes, respectively, after 5-minute incubation, values similar to what has been reported previously in hepatocytes and hepatoma cells (15, 19) . Approximately 2% of added HNE was detected as DHN in liver homogenates, while DHN levels were at the limit of detection and less than 1% of added HNE in cerebral cortex homogenates and synaptosomes (not shown).
Since the loss of HNE could not be accounted for by the MAP pathway, oxidation, or reduction, we considered another possible explanation for the difference between total HNE loss and MAP metabolism in brain preparations. While others have repeatedly shown that only a small fraction of total HNE added to liver homogenates or cells binds to protein (20) , protein adduction by HNE may be greater in brain than liver, thereby accounting for the loss of HNE. We tested this hypothesis by determining the amount of radioactivity incorporated into the protein fraction of each tissue preparation following 5-min incubation with 3 H-HNE (Fig. 3) . There was no difference among the 3 tissue preparations in the amount of radioactivity bound to protein.
Metabolism of HNE by Human Cerebral Cortex
The same metabolic routes for HNE detoxification investigated in rat tissue were examined in the middle frontal gyrus from 4 patients with AD (average age ϭ 80 Ϯ 3 yr; PMI ϭ 2.8 Ϯ 0.2 h; and female:male ϭ 1:1) and 4 age-matched controls (average age ϭ 78 Ϯ 2 years; PMI ϭ 2.6 Ϯ 0.2 h; and female:male ϭ 3:1). Human cerebral cortex consumed HNE at a rate similar to rat cerebral cortex (Fig. 4) ; 53% or 47% was consumed in AD or control tissue at 5 min, respectively. Consumption of HNE was significant only for time (p Ͻ 0.0001) but not for AD vs control. H-HNE for 1 to 5 min and the percentage of total radioactivity added that was enzymatically converted into hydrophilic products determined. Twoway ANOVA (F 1, 5, 84 ) showed that the amount of HNE converted to hydrophilic metabolites in AD patients was significantly greater than controls (p Ͻ 0.001).
all times Ն1 min, achieving approximately 10% conversion of HNE to hydrophilic metabolites after 5 min (Fig.  4B) . The amount of HNE enzymatically converted to hydrophilic metabolites in AD patients was significantly greater than controls (p Ͻ 0.001). As with brain preparations from rat, total HNE consumption vs MAP metabolism in AD patients or controls was highly significant for metabolic pathway (p Ͻ 0.0001 for both groups of individuals) and time (p Ͻ 0.0001 for both groups of individuals). Less than 1% of added HNE was detected as HNA or DHN in human brain homogenate from AD patients or controls throughout the 5-min time course (not shown).
Immunohistochemistry
We further investigated MAP metabolism by immunohistochemical localization of the major cytosolic GSTs in the regions of brain that degenerate in AD. GST immunoreactivity was evaluated in frontal cortex and medial temporal lobe structures in 6 patients with AD (average age ϭ 78 Ϯ 2 yr; PMI ϭ 2.6 Ϯ 0.1 h; and female: male ϭ 2:1) and 6 age-matched controls (average age ϭ 80 Ϯ 2 yr; PMI ϭ 2.9 Ϯ 0.2 h; and female:male ϭ 1:1). The appropriate positive control tissue specified by the manufacturer and prepared identically to brain tissue was immunoreactive with the appropriate antiserum, but not with other antiserum. For example, human small intestinal epithelium was immunoreactive for GST-alpha but not for GST-pi or GST-mu (not shown). In brain sections from both control and AD patients, GST-pi immunoreactivity was uniformly widespread in gray and white matter of both cerebral cortex and hippocampus and found in virtually all astrocytes and endothelial cells with only scattered immunoreactive neurons, similar to what has been described in rodent brain (21, 22 ) and what we have illustrated in other regions of human brain (18) . GST-mu immunoreactivity was more restricted than GST-pi. In the cerebral cortex of both control and AD patients, GST-mu was concentrated in gray matter with no immunoreactivity in white matter. In cortical gray matter, GST-mu immunoreactivity localized mostly to pyramidal neuron soma, especially in the deeper layers, with some scattered reactivity in glia (Fig. 5A) . In addition, GST-mu immunoreactivity was unevenly spread among regions of hippocampus with high immunoreactivity in the dentate gyrus, CA3, and CA4, but no detectable immunoreactivity in other regions of hippocampus (Fig. 5B) ; in these regions, pyramidal neuron soma and neuropil, but not astrocyte soma, showed GST-mu immunoreactivity (Fig.  5D) . Although the characteristic loss of neurons and gliosis was observed in hippocampus from AD patients, the regional distribution of hippocampal GST-mu immunoreactivity was similar between AD patients and controls. GST-alpha immunoreactivity was not detectable in cerebral cortex or hippocampus. Thus, the regional distribution and cellular localization of GST-alpha, -mu, and -pi immunoreactivity was not different between controls and patients with AD. However, the reactive astrocytes characteristic of diseased regions of AD brain tissue were prominently immunoreactive with GST-pi (Fig. 5C ) and GST-mu (not shown).
DISCUSSION
HNE is a potent neurotoxin formed in brain from oxidative damage to polyunsaturated fatty acids, and its levels are increased in several neurodegenerative diseases including AD, where HNE is proposed to be a neurotoxic effector of amyloid (A) ␤ peptide-mediated neurotoxicity. MAP detoxification of HNE is a critical means by which other organs limit its deleterious effects; however, MAP metabolism of HNE in brain has been investigated only partially. Here we examined the distribution and activity of MAP detoxification of HNE in regions of brain involved by AD.
Liver homogenate was used as positive control and was more efficient at clearing HNE than either cerebral cortical homogenate or synaptosomes. We selected 100 M HNE for these experiments to insure pseudo-first order conditions in our in vitro experiments. While this concentration of HNE is toxic to cells in culture, others have shown that concentrations of HNE in cerebrospinal fluid of AD patients average 30 M and range as high as 180 M (7). As has been repeatedly observed by others, liver efficiently cleared virtually all HNE through the MAP (15, 19, 23) . There were 2 important differences in HNE metabolism between rat brain and liver. First, loss of free HNE was significantly less in both cerebral cortex homogenates and synaptosomes compared to liver homogenates from the same rats, with liver homogenates converting approximately 1.5-fold more HNE than the preparations derived from brain. Second, there was an even greater difference in MAP metabolism between liver and brain; MAP metabolism in cerebral cortex and synaptosomes accounted for only a fraction of HNE loss, unlike in liver where MAP metabolism was equivalent to total loss of HNE. Indeed, a large part of the difference in the amount of HNE lost from these tissues can be explained by differences in MAP activity. Possible explanations for the lower MAP metabolism of HNE in cerebral cortex and synaptosomes are that GSTs are less abundant or that there is a different composition of isozymes in these tissue preparations. Regardless of the precise mechanism, these data demonstrate that cerebrum, especially the terminal compartment, has reduced capacity to metabolize HNE compared to liver, that this is due at least in part to diminished MAP metabolism, and suggest one possible explanation for why brain tissue is particularly vulnerable to the deleterious effects of lipid peroxidation.
Given the discrepancy between HNE clearance and MAP metabolism in rat brain preparations, we tested several other metabolic pathways for HNE detoxification. Our results showed that oxidation and reduction products of HNE were generated in only very small amounts. Although the activity in these pathways as quantified in our experiments may not accurately reflect their activity in vivo because of limitation by co-factor concentrations, these experiments did show that neither metabolic oxidation nor reduction could account for the discrepancy between HNE loss and MAP metabolism observed in vitro. In addition, we determined that protein adduction by HNE was at the same low levels as that of liver and did not account for a significant proportion of HNE lost. Thus, although we and others have shown that liver metabolism of HNE is largely accomplished by MAP metabolism with smaller contributions from enzymatic oxidation, enzymatic reduction, or protein adduction (20) , our results demonstrated that a significant fraction of HNE clearance from brain tissue cannot be explained by these established pathways.
We and others have localized the family of enzymes that catalyze the committed step in the MAP, the GSTs, in rodent and human brain (18, 24, 25) . However, these studies have not specifically investigated the regions of brain involved in AD. Similar to what we observed previously in human striatum, GST-pi was widely distributed in cerebral cortex and hippocampus, GST-mu had a more restricted distribution of immunoreactivity, and GST-alpha was not detectable in either region of brain. It is important to note that others have shown that a subclass of GST-alpha, hGSTA4-4, is most efficient at catalyzing adduction of GSH to HNE and that hGSTA4-4 is expressed in human brain (26) (27) (28) . The antibody to GSTalpha used in these experiments was strongly positive in small intestinal epithelium, a tissue with abundant h-GSTA4-4 (29) . In combination, these results suggest that hGSTA4 is present in human brain but at levels below the limit of detection for the immunohistochemical methods used in our experiments.
In addition to hGSTA4-4, other alpha, mu, and pi GST isozymes catalyze the detoxification of HNE (11, 28, (30) (31) (32) (33) (34) (35) (36) . The cellular and regional localization of GST-pi and GST-mu in cerebral cortex and hippocampus were similar between AD patients and controls; however, both GSTs displayed prominent immunoreactivity with reactive astrocytes in AD patients. While this is a qualitative finding, when coupled with the increased conversion of HNE to hydrophilic metabolites in cerebral cortex from AD patients versus controls, these data suggest that reactive changes in AD frontal cortex may include enhanced MAP activity. Using a test compound that is preferentially metabolized by GST-pi, others have shown unchanged GST activity in frontal cortex of AD patients and reduced GST activity in other regions of brain involved by AD compared with controls (34) . Interpreting our data in light of their results suggests that GST-mu may be a significant contributor to MAP metabolism of HNE in regions of brain affected by AD. In combination, these findings suggest that there is a slight but significant increase in MAP detoxification of HNE in frontal cortex of patients with AD.
In conclusion we have demonstrated that rat cerebral cortex and especially the synaptosome compartment are less well equipped to detoxify HNE via the MAP compared to liver. Moreover, we have shown that GST-mu and GST-pi, but not GST-alpha, are detectable immunohistochemically in neurons and astrocytes in regions of brain affected by AD and that MAP metabolism is modestly but significantly increased in AD frontal cortex compared to control. Taken together, the significantly lower MAP activity in cerebral cortex and synaptosomes compared to liver suggests that lipid peroxidation may present a greater toxic burden to cerebrum, and that a component of response to injury in diseased regions of brain late in the course of AD is a slight increase in MAP activity.
